Trending News on Targeted Oncology, Week of October 30, 2020

This week, the FDA granted approval to the FoundationOne Liquid biopsy assay as a companion diagnostic for several indications.

The FDA also granted an Orphan Drug designation for soft tissue sarcoma, a Priority Review designation for PD-L1-high advanced or metastatic non–small cell lung cancer (NSCLC), as well as a Priority Review for HER2-positive metastatic gastric/gastroesophageal junction adenocarcinoma.

These updates and others were trending:

Adjuvant Osimertinib Induces Promising CNS FDS in Early Stage EGFR-Mutant NSCLC​

In an interview with Targeted Oncology, Masahiro Tsuboi, MD, discussed the findings from the ADAURA study, which explored the role of osimertinib (Tagrisso) as treatment of patients with early-stage EGFR-mutant NSCLC following a complete tumor resection.

Novel IDH1 Inhibitor Demonstrates Safety and Preliminary Efficacy in R/R AML​

The IDH1 inhibitor olutasidenib showed a favorable safety profile in patients with relapsed/refractory acute myeloid leukemia treated in a phase 1/2 clinical trial.

PSMA Sparks Interest for Detection and Targeting in Men With Prostate Cancer​

In an interview with Targeted Oncology, Naomi Haas, MD, discussed the role of PSMA in the treatment landscape of prostate cancer and highlighted the key findings from the phase 1 chimeric antigen receptor T-cell trial in metastatic castration resistance prostate cancer.

Adagrasib Demonstrates Significant Disease Control in KRAS G12C+ Non-Small Cell Lung Cancer​

Adagrasib (MRTX849) demonstrated promising antitumor activity as monotherapy in patients with previously treated KRAS G12C–mutant NSCLC.

High-Risk MCL Population Represents Unmet Need in Treatment Landscape​

The treatment landscape of mantle cell lymphoma has been enriched with the development of several targeted therapies, but patients considered to have high-risk disease tend to have a worse prognosis, despite the latest development in the field.

Immunotherapy Combinations Improve Survival in Advanced Renal Cell Carcinoma​

Bradley McGregor, MD, discusses the current treatment landscape for patients with advanced or metastatic renal cell carcinoma, which has significantly evolved over the last few years.

Expanding Options for Treatment of CLL Using BTK Inhibitors​

Jennifer R. Brown, MD, PhD, and Alan Skarbnik, MD, describe the rationale for treating chronic lymphocytic leukemia with BTK inhibition, and explore current trends in data that impact treatment selection.

Special Feature: COVID-19

How to Leverage Real-World Data as COVID-19 Transforms Clinical Trials

Due to efforts to reduce exposure to the coronavirus, oncology patient volumes initially decreased, treatment regimens were disrupted or altered, and new cancer diagnoses also slowed. This affected not only patient care, but also clinical trials.